Jury says Apple owes Masimo $634M for patent infringement

A federal jury in California has ordered Apple to pay medical device maker Masimo $634 million for infringing a patent on blood oxygen monitoring technology used in the Apple Watch's workout mode and heart rate notification features. Masimo hailed the verdict as a win for intellectual property protection, while Apple announced plans to appeal, asserting the patent expired in 2022 and relates to outdated technology. This ruling marks a significant development in the companies' protracted legal dispute, which previously resulted in an import ban on Apple Watches featuring blood oxygen monitoring.

Analysis

A federal jury has ordered Apple (AAPL) to pay medical device maker Masimo (MASI) $634 million for infringing a patent related to blood oxygen monitoring technology used in the Apple Watch's workout and heart rate notification features. This significant verdict follows Masimo's assertion that Apple violated its intellectual property, marking a substantial financial penalty for Apple. The overall sentiment for AAPL is notably negative (-0.7) following this news, while MASI's sentiment is strongly positive (0.7).

This ruling is a critical development in a protracted legal battle, which previously saw the U.S. International Trade Commission ban imports of Apple Watches with blood oxygen monitoring in 2023. Apple's subsequent attempt to circumvent this ban with a new feature, calculating readings on the paired iPhone, indicates the strategic importance of this technology. Masimo's commitment to defending its IP rights underscores the high stakes involved for both companies.

Masimo has hailed the verdict as a win for innovation protection, while Apple has announced plans to appeal, arguing the patent expired in 2022 and pertains to outdated technology. The appeal process introduces uncertainty regarding the final financial obligation and the long-term availability of blood oxygen monitoring features on Apple Watches. Apple's prior successful countersuit against Masimo for $250 highlights the complex and multi-faceted nature of this litigation.

Key Decisions for Investors

• Monitor Apple's (AAPL) appeal process closely, as the outcome will determine the final financial impact and potential product feature implications for its wearables segment.
• Assess the long-term implications of this verdict on Apple's intellectual property strategy and its ability to integrate health features into its devices, considering the precedent set for patent infringement.
• Evaluate Masimo's (MASI) enhanced market position and potential for future licensing opportunities or further legal actions, given its successful defense of key patents and the substantial award.